文献速递创伤与烧伤心脑血管急症重症综合管理与镇静镇痛

临床批准剂量丙戊酸改善失血性休克合并创伤性脑损伤猪的神经功能恢复并减小脑损伤体积

Administration of valproic acid in clinically approved dose improves neurologic recovery and decreases brain lesion size in swine subjected to hemorrhagic shock and traumatic brain injury.
PubMed 文献 · J Trauma Acute Care Surg · 2021-01-01
一句话结论在失血性休克合并TBI的猪模型中,临床批准剂量的丙戊酸(50 mg/kg)可减小脑损伤体积并加速神经功能恢复。

本研究为动物实验(猪),比较失血性休克合并TBI后单次给予丙戊酸50 mg/kg或150 mg/kg与单纯生理盐水复苏的效果。结果显示,丙戊酸组在伤后第1天神经功能损害显著较轻,且恢复至基线更快;伤后第3天MRI显示脑损伤体积显著小于对照组。50 mg/kg为FDA已批准临床使用剂量,提示该剂量可能具有神经保护作用,但需进一步临床验证。

要点

  • 在失血性休克合并TBI的猪模型中,单次丙戊酸50 mg/kg或150 mg/kg均较单纯生理盐水复苏显著减轻伤后第1天神经功能损害(神经严重程度评分:对照组22±3 vs VPA 150组8±7或VPA 50组6±6;p=0.02和0.003)。
  • 丙戊酸治疗组脑损伤体积显著小于对照组(对照组1268.0±241.2 mm³ vs VPA 150组620.4±328.0 mm³或VPA 50组438.6±234.8 mm³;p=0.007和0.001)。
  • 丙戊酸50 mg/kg为FDA已批准临床使用剂量,在本模型中显示出与150 mg/kg相似的神经保护趋势。
  • 该研究为动物实验(每组n=5),结果需在临床人群中进一步验证,不能直接作为临床推荐剂量。

适用人群与场景

  • 适用人群与场景:失血性休克合并创伤性脑损伤的猪模型(每组n=5),非人类临床研究。

诊断标准与关键阈值

  • 诊断标准与关键阈值:原文未提及。

处置流程与药物剂量

  • 处置流程与药物剂量:在失血性休克合并TBI的猪模型中,经生理盐水复苏后,单次给予丙戊酸50 mg/kg或150 mg/kg(具体给药途径、频次原文未提及);对照为单纯生理盐水复苏。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究设计:动物实验(猪),每组n=5,随机分为对照组(单纯生理盐水复苏)、VPA 150 mg/kg组和VPA 50 mg/kg组。
  • 主要终点:伤后第1天神经严重程度评分(0-32)对照组22±3,VPA 150组8±7,VPA 50组6±6(p=0.02和0.003)。
  • 次要终点:伤后第3天MRI脑损伤体积对照组1268.0±241.2 mm³,VPA 150组620.4±328.0 mm³,VPA 50组438.6±234.8 mm³(p=0.007和0.001)。
  • 不良事件:原文未提及。

证据类型、等级与局限

  • 证据类型:动物实验(猪),非随机对照临床试验;原文未给出证据等级或推荐强度。
  • 局限性:样本量小(每组n=5),动物模型,结果需临床验证。

对床旁实践的改变

  • 对床旁实践的改变:原文结果提示丙戊酸50 mg/kg(FDA已批准临床剂量)在失血性休克合并TBI模型中可能减轻神经功能损害和脑损伤体积,但尚无人类临床证据,不能改变当前临床实践;适用人群与不适用人群原文未明确。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Traumatic brain injury (TBI) and hemorrhage remain the leading causes of death after trauma. We have previously shown that a dose of valproic acid (VPA) at (150 mg/kg) can decrease brain lesion size and hasten neurologic recovery. The current Food and Drug Administration-approved dose of VPA is 60 mg/kg. We evaluate neurologic outcomes and brain lesion size of a single dose of VPA at a level currently within Food and Drug Administration-approved dose in swine subjected to TBI and hemorrhagic shock.

METHODS: Swine (n = 5/group) were subjected to TBI and 40% blood volume hemorrhage. Animals remained in shock for 2 hours before randomization to normal saline (NS) resuscitation alone (control), NS-VPA 150 mg/kg (VPA 150), or NS-VPA 50 mg/kg (VPA 50). Neurologic severity scores (range, 0-32) were assessed daily for 14 days, and brain lesion size was measured via magnetic resonance imaging on postinjury day (PID) 3.

RESULTS: Shock severity and laboratory values were similar in all groups. Valproic acid-treated animals demonstrated significantly less neurologic impairment on PID 1 and returned to baseline faster (PID 1 mean neurologic severity score, control = 22 ± 3 vs. VPA 150 mg/kg = 8 ± 7 or VPA 50 mg/kg = 6 ± 6; p = 0.02 and 0.003). Valproic acid-treated animals had significantly smaller brain lesion sizes (mean volume in mm3, control = 1,268.0 ± 241.2 vs. VPA 150 mg/kg = 620.4 ± 328.0 or VPA 50 mg/kg = 438.6 ± 234.8; p = 0.007 and 0.001).

CONCLUSION: In swine subjected to TBI and hemorrhagic shock, VPA treatment, in a dose that is approved for clinical use, decreases brain lesion size and reduces neurologic impairment compared with resuscitation alone.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Wakam GK, Biesterveld BE, Pai MP, et al. Administration of valproic acid in clinically approved dose improves neurologic recovery and decreases brain lesion size in swine subjected to hemorrhagic shock and traumatic brain injury. J Trauma Acute Care Surg. 2021. PMID: 33230090. doi:10.1097/TA.0000000000003036

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。